UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interpretation and use of FRAX in clinical practice

Osteoporosis international, 2011-09, Vol.22 (9), p.2395-2411

2011

Volltextzugriff (PDF)

SP0169 Pharmacological Management of Osteoporosis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.41-41

Papapoulos, S.

2016

Volltextzugriff (PDF)

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

Osteoporosis international, 2021-02, Vol.32 (2), p.251-259

2021

Volltextzugriff (PDF)

SP0011 Modern Treatment of Osteoporosis; The First 5 Years

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.4-4

Papapoulos, S.

2015

Volltextzugriff (PDF)

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Osteoporosis international, 2015-02, Vol.26 (2), p.699-712

2015

Volltextzugriff (PDF)

Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site

Osteoporosis international, 2017-08, Vol.28 (8), p.2433-2437

2017

Volltextzugriff (PDF)

Sclerostin: Current Knowledge and Future Perspectives

Calcified tissue international, 2010-08, Vol.87 (2), p.99-107

2010

Volltextzugriff (PDF)

Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures

Osteoporosis international, 2022-07, Vol.33 (7), p.1511-1519

2022

Volltextzugriff (PDF)

Denosumab for the treatment of primary pediatric osteoporosis

Osteoporosis international, 2021-11, Vol.32 (11), p.2377-2381

2021

Volltextzugriff (PDF)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Osteoporosis international, 2015-12, Vol.26 (12), p.2773-2783

2015

Volltextzugriff (PDF)

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

European journal of endocrinology, 2010-11, Vol.163 (5), p.833-837

2010

Volltextzugriff (PDF)

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Osteoporosis international, 2019-01, Vol.30 (1), p.71-78

2019

Volltextzugriff (PDF)

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Journal of bone and mineral research, 2012-03, Vol.27 (3), p.694-701

2012

Volltextzugriff (PDF)

Goal-directed treatment of osteoporosis in Europe

Osteoporosis international, 2014-11, Vol.25 (11), p.2533-2543

2014

Volltextzugriff (PDF)

Bisphosphonates

Bone (New York, N.Y.), 2011-05, Vol.48, p.S52-S52

Papapoulos, S

2011

Volltextzugriff (PDF)

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

Osteoporosis international, 2011-02, Vol.22 (2), p.373-390

2011

Volltextzugriff (PDF)

Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper

Calcified tissue international, 2012-05, Vol.90 (5), p.343-353

2012

Volltextzugriff (PDF)

Sclerostin in Mineralized Matrices and van Buchem Disease

Journal of dental research, 2009-06, Vol.88 (6), p.569-574

2009

Volltextzugriff (PDF)

Bone fragility in patients affected by congenital diseases non skeletal in origin

Orphanet journal of rare diseases, 2021-01, Vol.16 (1), p.11-11, Article 11

2021

Volltextzugriff (PDF)

Serum Dickkopf 1 Levels in Sclerostin Deficiency

The journal of clinical endocrinology and metabolism, 2014-02, Vol.99 (2), p.E252-E256

2014

Volltextzugriff (PDF)

Technical note: Recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation

Bone Reports, 2016-12, Vol.5, p.181-185

2016

Volltextzugriff (PDF)

Treatments of osteoporosis increase bone material strength index in patients with low bone mass

Osteoporosis international, 2020-09, Vol.31 (9), p.1683-1690

2020

Volltextzugriff (PDF)

Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates

Bone (New York, N.Y.), 2003-11, Vol.33 (5), p.805-811

2003

Volltextzugriff (PDF)

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

European journal of endocrinology, 2012-04, Vol.166 (4), p.711-716

2012

Volltextzugriff (PDF)

Circulating Sclerostin Levels Are Decreased in Patients with Endogenous Hypercortisolism and Increase after Treatment

The journal of clinical endocrinology and metabolism, 2012-10, Vol.97 (10), p.E1953-E1957

2012

Volltextzugriff (PDF)

1 – 25 von 673

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(465)
Mit Volltextzugriff
(569)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(292)
Life Sciences & Biomedicine
(290)
Humans
(279)
Female
(179)
Endocrinology & Metabolism
(174)
Biological And Medical Sciences
(169)
Medical Sciences
(134)
Male
(124)
Middle Aged
(117)
Osteoporosis
(114)
Aged
(100)
Animals
(85)
Adult
(81)
Bisphosphonates
(64)
Orthopedics
(63)
Diphosphonates - Therapeutic Use
(62)
General & Internal Medicine
(58)
Mice
(58)
Fundamental And Applied Biological Sciences. Psychology
(57)
Pharmacology. Drug Treatments
(56)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Interpretation and use of FRAX in clinical practice

SP0169 Pharmacological Management of Osteoporosis

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

SP0011 Modern Treatment of Osteoporosis; The First 5 Years

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site

Sclerostin: Current Knowledge and Future Perspectives

Bone material strength index as measured by in vivo impact microindentation is normal in subjects with high-energy trauma fractures

Denosumab for the treatment of primary pediatric osteoporosis

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

Goal-directed treatment of osteoporosis in Europe

Bisphosphonates

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper

Sclerostin in Mineralized Matrices and van Buchem Disease

Bone fragility in patients affected by congenital diseases non skeletal in origin

Serum Dickkopf 1 Levels in Sclerostin Deficiency

Technical note: Recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation

Treatments of osteoporosis increase bone material strength index in patients with low bone mass

Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates

Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus

Circulating Sclerostin Levels Are Decreased in Patients with Endogenous Hypercortisolism and Increase after Treatment

Suchergebnisse filtern